SCIESCOPUSQ1
MOLECULAR CANCER THERAPEUTICS
AMER ASSOC CANCER RESEARCH, United States
MOLECULAR CANCER THERAPEUTICS is an academic journal published by AMER ASSOC CANCER RESEARCH (United States). Identifiers: ISSN 1535-7163, eISSN 1538-8514. Indexed in SCIE, SCOPUS. Metrics: JIF 5.5, CiteScore 11.0, SJR 2.493, SNIP 1.14. Subject areas: ONCOLOGY. tlooto lists 12,490 papers from this journal.
CiteScore
11.00
Scopus उद्धरण मापदंड
SJR
2.493
SCImago रैंक
SNIP
1.14
स्रोत-सामान्यीकृत प्रभाव
प्रतिशत रैंक
-
JIF प्रतिशतक रैंक
जर्नल प्रोफ़ाइल
- ISSN
- 1535-7163
- eISSN
- 1538-8514
- संक्षेप
- MOL CANCER THER
- प्रकाशक
- AMER ASSOC CANCER RESEARCH
- देश
- United States
Web of Science श्रेणियाँ
SCIEONCOLOGY
Scopus ASJC श्रेणियाँ
1306 Cancer Research2730 Oncology
कीवर्ड
Oncology
Papers in this journal
Recent papers
- BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.
2026
- Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
2026
- Targeting the chromatin modifying enzyme, KDM5C, enhances AKT inhibition response in ER+ breast cancer.
2026
- PRMT5 Inhibition by SCR-6920 Downregulates HIF-1α and Exhibits Synergistic Antitumor Activity with Bevacizumab in Ovarian Cancer.
2026
- Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition.
2026
Most cited papers
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
2015 · 1,988 citations
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
2017 · 1,955 citations
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
2008 · 1,379 citations
- Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
2004 · 1,204 citations
- The Role of Autophagy in Cancer: Therapeutic Implications
2011 · 1,198 citations